Wild-type mumps viruses (MuVs) are highly neurotropic and, prior to widespread vaccination programmes, were a major cause of viral meningitis and encephalitis in most developed countries. At present, there are no markers for virus attenuation, apart from the failure of a passaged isolate to produce clinical symptoms in vaccinees. Indeed, some MuV vaccines have retained residual neurovirulence properties and have caused aseptic meningitis in vaccinees. Three amino acid changes associated with the neuroattenuation of a wild-type MuV strain were identified previously. This study evaluated the impact of these changes on the function of the respective proteins. The data demonstrated that the SerAAsp amino acid substitution at position 466 in the haemagglutinin-neuraminidase protein resulted in decreased receptor binding and neuraminidase activity, the Ala/ThrAThr selection in the fusion protein resulted in decreased fusion activity, and the IleAVal substitution in the polymerase resulted in increased replicative/transcriptional activity. These data suggest a polygenic component (i.e. specific and inter-related roles of these amino acid changes) to MuV neuroattenuation.
INTRODUCTION
Mumps virus (MuV), a member of the family Paramyxoviridae, is a 15.4 kb non-segmented, negative-stranded, enveloped RNA virus. The viral genome encodes open reading frames (ORFs) for the nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), small hydrophobic protein (SH), haemagglutinin-neuraminidase protein (HN) and the polymerase (L) (Carbone & Rubin, 2007; Elango et al., 1988) . Through an RNA editing mechanism, the P gene also encodes the V and I proteins (Paterson & Lamb, 1990) . MuV typically causes a mild respiratory infection; however, evidence of infection of the central nervous system has been reported in approximately half of all clinical cases (Bang & Bang, 1943) . Neurological manifestations include aseptic meningitis (Beghi et al., 1984; Rotbart, 2000) and, more rarely, encephalitis (Aygun et al., 2001; Beghi et al., 1984) , obstructive hydrocephalus (Ogata et al., 1992; Timmons & Johnson, 1970) , transverse myelitis (Caksen & Ustunbas, 2003) and cerebellar ataxia (Cohen et al., 1992) . The introduction of MuV vaccination programmes worldwide has resulted in a dramatic reduction in the number of mumps cases and, in some countries, the disease has almost been eliminated (Galazka et al., 1999; Peltola et al., 2000; Slater et al., 1999) . However, as disease incidence has declined, concerns about vaccine safety have increased. For example, aseptic meningitis following the use of some vaccines, e.g. Urabe AM9, has resulted in vaccine withdrawal and public resistance to vaccination (Furesz & Contreras, 1990; Miller et al., 1993; Sugiura & Yamada 1991; Ueda et al., 1995) . The need for robust immunization programmes and maintenance of public confidence in vaccines has been highlighted by the recent massive mumps epidemics in the USA and UK (Centers for Disease Control and Prevention, 2006; Gupta et al., 2005; Savage et al., 2005) .
To support the development and use of safe MuV vaccines, a rat-based test that appears capable of accurately assessing the human neurovirulence potential of MuV strains was developed (Rubin et al., 2000 (Rubin et al., , 2005 . Using this prototype neurovirulence safety test, we previously reported the identification of three amino acid changes associated with neuroattenuation of the highly neurovirulent wild-type MuV strain: one each in the F (Ala/Thr91AThr), HN (Ser-466AAsn) and L (Ile-736AVal) proteins . To understand the basis for virus neuroattenuation in more detail, this study characterized the effect of these amino acid changes on the function of the corresponding proteins. Our results indicated that, relative to the wild-type parental virus strain, the amino acid substitution in the HN protein of the attenuated virus resulted in decreased receptor binding (haemagglutination) and release (neuraminidase) activities, whilst the amino acid selection in the F protein resulted in a dramatic decrease in fusion activity. Lastly, the amino acid substitution in the polymerase protein resulted in increased replicative/transcriptional properties of the protein.
Potential ways in which these three amino acid changes, individually or in combination, may directly impact on virus virulence in vivo are discussed, but cannot be firmly ascertained until the development of a reverse-genetics system for this and other wild-type MuV strains.
METHODS
Cell lines and viruses. Vero cells, HeLa cells and chicken embryo fibroblasts (CEF) were maintained in Dulbecco's modified Eagle's medium (DMEM; Quality Biological) supplemented with 10 % fetal bovine serum (FBS). BHK-BSR-T7/5 cells (Buchholz et al., 1999) , kindly provided by K. Conzelmann (Munich, Germany), were maintained in DMEM supplemented with 10 % FBS and 1 mg neomycin (Invitrogen) ml 21 . The modified vaccinia virus Ankara strain expressing T7 RNA polymerase (MVA-T7) was kindly provided by B. Moss (Bethesda, MD, USA) and propagated in primary CEF cells (Wyatt et al., 1995) . The neurovirulent 88-1961 wild-type MuV strain (88-1961 WT ) and its CEF-passaged neuroattenuated derivative (88-1961 ATT ) have been described previously Rubin et al., 2003) .
RNA isolation, RT-PCR and sequencing. MuV RNA was extracted from 88-1961-infected Vero cells using an RNAeasy kit (Qiagen) or from MuV stocks using a QIAamp Mini-elute Virus Spin kit (Qiagen). Reverse transcription (RT) reactions were performed with an appropriate gene-specific primer and Superscript II reverse transcriptase (Invitrogen). PCRs were performed with Pfx polymerase (Invitrogen). Optimal PCR conditions were determined empirically for each primer set. PCR fragments and plasmids were sequenced on an ABI 3100 automated capillary DNA sequencer. Sequence data were analysed using CHROMAS (Technelysium Pty Ltd), JELLYFISH (LabVelocity) and IMAGE-PRO PLUS 4.5 (Media Cybernetics) software packages.
Assessment of heterogeneity within the wild-type 88-1961F
ORF. The consensus sequence of 88-1961 WT contains a heterogeneous nucleotide (A/G) population at position 271 of the F ORF, encoding either Ala or Thr at aa 91 . In order to assess accurately the impact of this mixed nucleotide population on fusogenicity, the F ORF was amplified by RT-PCR using primers F1 (59-GGCTTTCTCAGTTATTTGCTTGG-39) and F2 (59-CCTGATG-AGATCATCGACACTACTTG-39), using viral RNA isolated from a lysate of 88-1961 WT , in three independent reactions. The PCR fragment from each of the three reactions was sequenced and measurements of the area under the curve were performed to determine the ratio of A : G using IMAGE-PRO PLUS 4.5 software.
Construction of plasmids. Total RNA isolated from 88-1961-infected Vero cells was used for RT-PCR amplification of all viral sequences. Restriction sites introduced into the primers used for RT-PCR are highlighted below in bold and all final constructs were sequenced completely to ensure homology with the published sequence (GenBank accession no. AF467767).
Expression plasmids for the HN and F genes. The F ORF containing an A at nt 271 was amplified by RT-PCR using the following primers: F-P1-BspHI (59-TGCTCATGAAGGCTTTCTCAGTTATTT-GCTTGG-39) and F-P2-XhoI (59-CCTCTCGAGTTAGTACCTGATG-AGATCATCG-39). The PCR fragment was digested with BspHI and XhoI and ligated into the pTM1 vector (kindly provided by B. Moss; Moss et al., 1990) between the T7 RNA polymerase promoter and terminator sequences, respectively, at the NcoI/XhoI sites. The resulting plasmid, p-F Thr , was modified by site-directed mutagenesis (SDM) to introduce a G at nt 271 using the QuikChange SDM kit (Stratagene). The resultant plasmid was termed p-F Ala . To represent the previously reported nucleotide substitution in HN (GAA at nt 1397), a wild-type HN expression plasmid containing a G at nt 1397 was constructed by amplifying two PCR fragments using primer pairs HN-P1-NcoI (59-TGCCCATGGAACCCTCAAAACTCTTCACAATA-TC-39) and HN-P2-NcoI (59-CGAGAATCCCCATGGAAACATAT-TGGTTAGACG-39), and HN-P3-NcoI (59-CGTCTAACCAATATG-TTTCCATGGGGATTCTCG-39) and HN-P4-XhoI (59-CCTCTCG-AGTCAAGTGATAGTCAATCTGGTTAGC-39). The PCR fragments were digested with the appropriate restriction enzymes and ligated contiguously into the pTM1 vector at the NcoI/XhoI sites. The resultant plasmid, p-HN WT , was modified by SDM to introduce an A at nt 1397. The modified plasmid was termed p-HN ATT .
Expression plasmids for the N, P and L genes. RT-PCR amplification of the N ORF was performed using primers N-P1-BspHI (59-TGCTCATGAGCTCTGTGCTCAAAGCGTTTG-39) and N-P2-XhoI (59-CCGCTCGAGTTACTCATCCCAGTCACC-39). The PCR fragment was digested with BspHI and XhoI and ligated into the pTM1 vector at the NcoI/XhoI sites. The resultant plasmid was termed p-N.
RT-PCR amplification of the P ORF was performed using primers P-P1-NcoI (59-TGCCCATGGATCAGTTTATAAAACAGGATGAG-39) and P-P2-XhoI (59-CCGCTCGAGTCATATGGCGCTTCGTATG-39). The PCR fragment was digested with NcoI and XhoI and ligated into the pTM1 vector at the NcoI/XhoI sites. The P ORF was subsequently modified by SDM to introduce two additional Gs at position 463 (Paterson & Lamb, 1990) . The resultant plasmid was termed p-P.
Due to the large size of L, the wild-type L ORF containing an A at nt 2206 was amplified and assembled in three steps. L-P1-BamHI (59-GGCAATTCTTTTCAACAATAAGGATCCTGCG-39) and L-P2-PstI (59-CCACTGCAGTTAAATTATGTCTCCGTGG-39) amplified the 39 857 bp fragment, L-P3-NcoI (59-GCTAATAACCATGGAATTGGAC-ACCACC-39) and L-P4-BamHI (59-CGCAGGATCCTTATTGTTG-AAAAGAATTGCC39) amplified the middle 3.5 kb fragment, and L-P5-NcoI (59GGACCATGGATGGGCGTATCTCAGTTTTTATCG-39) and L-P6-NcoI (59-GGTGGTGTCCAATTCCATGGTTATTAGC-39) amplified the 2.5 kb 59 fragment. The three PCR fragments were digested with the appropriate restriction enzymes and cloned contiguously into pTM1 at the NcoI/PstI sites. The resultant plasmid, p-L WT , was modified by SDM to introduce a G at nt 2206 of the L ORF. This plasmid was termed p-L ATT .
Construction of the 88-1961 minireplicon, p88-1961CAT. A minireplicon containing the chloramphenicol acetyl transferase (CAT) reporter gene flanked by the 88-1961 gene start and gene end signals and by the genome termini was the final component constructed for use in the minigenome system. The following primers were used to amplify the 39 and 59 ends of 88-1961 WT , respectively: 39 P1-NarI (59-ATCATTGGCGCCAGCGAGGAGGCTGGGACCATGC-CGGCCACCAAGGGGAAAATGGAGATGGG-39) and 39 P2-BsmBI (59-ATCATTCGTCTCTTTTCAGGGTAGTGTCAAAATGTCTCCT-ATCAACAATGGAAGGTGAGGATCG-39), and 59 P1-BsmBI (59-ATCATTCGTCTCTATCGACTAGGGACTCCTCTGGT-39) and 59 P2-NotI (59-AAGCTCGGCGGCCGCTTGTAATACGACTCACTATA-ACCAAGGGGAGAAAGTAAAATC-39). Primer 39 P1-NarI encompassing the 88-1961 WT 39 end also encodes the hepatitis delta virus ribozyme sequence (italicized), whilst primer 39 P2-BsmBI, encompassing the 88-1961 WT 59 end, also encodes the sequence for the T7 RNA polymerase promoter (italicized). The following primers with BsmBI overhangs were used to PCR amplify the CAT ORF, using the Jeryl Lynn minireplicon (MUVCAT; Clarke et al., 2000) as template: CAT-P1 (59-ATCATTCGTCTCGGAAAATGGAGAAAAAAATCAC-TGGATATACCACCGTTGATATATCCC-39) and CAT-P2 (59-ATC-ATTCGTCTCTCGATTTACGCCCCGCCCTGCCACTC-39). The three PCR products were digested with the appropriate restriction enzymes and cloned in a four-way ligation into the pBluescript KS + -based MUVCAT minireplicon (Clarke et al., 2000) . MUVCAT was predigested with NotI/NarI to release all Jeryl Lynn and the previously cloned CAT-related sequences from the vector. The total number of nucleotides (966) were resolved by 7.5 % SDS-PAGE and transferred onto a nitrocellulose membrane (Towbin et al., 1979) . Polyclonal monospecific antibodies raised in rabbits against a peptide of the mumps HN protein cytoplasmic tail were used for the detection of HN by Western blotting (diluted 1 : 5000). Protein bands were visualized by staining with horseradish peroxidase-conjugated donkey anti-rabbit antibody (diluted 1 : 10000; Chemicon) followed by enhanced chemiluminescence (Amersham Biosciences). Band intensities were determined using QUANTITY ONE software (Bio-Rad).
Assessment of neuraminidase activity. To assess the role of the single amino acid change in the HN protein on neuraminidase activity, HeLa cells (1610 6 cells per well of a six-well plate) were infected with MVA-T7 (m.o.i.52.0) for 1 h at 37 uC and then transfected with 1 mg p-HN WT plus 1 mg pTM1, 1 mg p-HN ATT plus 1 mg pTM1, or 2 mg pTM1 (as assay control) using Lipofectamine (Invitrogen). At 24 h post-transfection (p.t.) the cell monolayers were washed twice with PBS and once with 0.1 M sodium acetate (pH 6) and incubated with 1 ml neuramin-lactose (625 mg ml
21
; SigmaAldrich) in 0.1 M sodium acetate (pH 6). Following incubation for 20 min at 37 uC, the neuraminidase activity of the HN variants was determined essentially as described by Aminoff (1961) . The supernatants were transferred to 15 ml polypropylene centrifuge tubes and incubated with 0.5 ml 25 mM periodic acid (in 62.5 mM H 2 SO 4 ). Following incubation at 37 uC for 1 h, 0.4 ml 2 % NaAsO 4 was added, the mixtures were vortexed and 2 ml of thiobarbituric acid (14.2 mg ml 21 , pH 9.0) was added. After boiling each sample for 7.5 min, an equal volume of acid butanol (5 % HCl) was added to extract the free sialic acid. The amount of free sialic acid was determined by reading the absorbance at 549 nm.
Following removal of the neuramin-lactose substrate from the transfected cell monolayers, the cells were washed three times with PBS and then harvested to quantify HN expression as described above. The neuraminidase activity of each HN variant was normalized for expression of HN at the cell surface.
Assessment of fusion activity. To assess the effects of the single amino acid changes in the F (amino acid selection) and HN (amino acid substitution) proteins on fusion activity, HeLa cells (1610 6 cells per well of a six-well plate) infected with MVA-T7 (m.o.i.52) for 1 h at 37 uC were co-transfected with combinations of p-HN WT , p-HN ATT , p-F Thr and p-F Ala (1 mg each), or 2 mg p-HN WT as control, using Lipofectamine. The fusion promotion activity of the expressed protein combinations was determined as described by Sergel et al. (1993) , with some modifications. The differences in size (number of nuclei per syncytium) and number of syncytia were quantified in five independent fields of view (1006 magnification) per well every 2 h for a total of 16 h p.t. To eliminate selection bias, fields of view were chosen based on a prescribed uniform pattern.
Assessment of F protein expression and processing. HeLa cells (1610 6 cells per well of a six-well plate) infected with MVA-T7 (m.o.i.52) for 1 h at 37 uC were transfected with 2 mg p-F Ala , p-F Thr or pTM1 (assay control) using Lipofectamine. At 36 h p.t., the cells were washed with cold PBS and membrane proteins isolated using a Compartmental Protein Extraction kit. The protein lysates (8 mg) were resolved by 7.5 % SDS-PAGE followed by Western blotting (Towbin et al., 1979) . F protein was detected with a rabbit MuV F anti-cytoplasmic tail polyclonal antibody (diluted 1 : 5000) (kindly provided by Dr Cattaneo, Mayo Clinic, Rochester, MN, USA; von Messling et al., 2004) . Protein bands were visualized by staining with a donkey anti-rabbit horseradish peroxidase-conjugated IgG (1 : 10 000) followed by enhanced chemiluminescence. Band intensities were determined using IMAGE-PRO PLUS 4.5 software. F protein expression and processing were evaluated based on the relative amounts and sizes of the unprocessed F 0 and processed F 1 subunits, respectively.
Assessment of polymerase activity. To assess the effect of the single amino acid change in the L protein on polymerase activity, BsrT7 cells grown on six-well plates to 70 % confluence were cotransfected using Lipofectamine with the minireplicon p88-1961CAT (200 ng) and the three support expression plasmids p-N (300 ng), p-P (50 ng) and either p-L WT or p-L ATT (100-600 ng). At 48 h p.t, the cells were lysed and CAT expression, used as an indicator of polymerase activity, was measured by CAT ELISA (Roche Biochemicals). The protein content of each sample was normalized using a BCA protein assay kit (Pierce) prior to determination of CAT expression.
RESULTS
SerAAsp substitution at position 466 of the neuroattenuated 88-1961 HN protein affects protein expression, virus-to-cell binding and neuraminidase activity
Attachment of MuV to target cellular receptors and nascent virion release from the cell surface are mediated by the HN protein. In order to determine the impact of the Ser466AAsp substitution on HN protein function, we assessed the ability of the 88-1961 WT and 88-1961 ATT viruses to bind RBCs, a standard method for evaluating relative differences in binding activities for paramyxoviruses. It should be noted that viruses were used here in lieu of HN-transfected cells due to the inability of transfected cells to express the high levels of HN protein required for this assay. In all other assays described in this paper, which are much more sensitive than the binding assay, transfected cells were used. As summarized in (Table 2) . Differences were also measured in neuraminidase activity associated with the Ser-466AAsp substitution in HN (Table 2) . In p-HN ATT -transfected cultures, neuraminidase activity was reduced by approximately 34 % compared with p-HN WT transfected cultures. The magnitude of this difference was decreased following normalization for cell-surface HN expression to approximately 23 % and statistical significance was marginally lost (P50.056, Student's t-test). Thus, despite the association of the HN Ser-466AAsp substitution with a decrease in cell-surface HN expression, the reduction in protein level did not account for decreased binding and neuraminidase activities on a per-HN molecule basis.
Selection of a Thr in the F protein, but not the SerAAsp substitution in the HN protein, affects fusogenicity
The multifunctional HN protein plays an integral role in virus-to-cell and cell-to-cell fusion in conjunction with the F protein (Tanabayashi et al., 1992; Tsurudome et al., 1986) . We have reported previously that neuroattenuation of 88-1961 WT was associated with the selection of an A residue from a previously heterogeneous A/G mixture at nt 271 of the F ORF . Electropherogram data indicated the A : G ratio in the wild-type virus to be approximately 1 : 1 (data not shown). To assess the effect of the loss of amino acid heterogeneity (Ala/Thr-91AThr) in F and that of the SerAAsp substitution in HN on fusion, an in vitro fusion assay was performed. In this assay HeLa cells were co-transfected with plasmids expressing the wildtype and attenuated F and HN proteins, and the number and size of resulting syncytia were quantified over time. (Fig. 1a, b) . In contrast, HeLa cells co-transfected with plasmids representing 88-1961 ATT not only displayed a delay in syncytium formation, but the number and size of syncytia was also significantly reduced over the same 16 h period (Fig. 1a, b) . Of note, the reduction in the number of syncytia in cultures co-transfected with wild-type F and HN following the 12 h time point was due to the merging of multiple syncytia to form single, large syncytia. To determine whether the decreased fusogenicity was due to F Thr or HN ATT , or both, HeLa cells were co-transfected with plasmids containing p-F Ala plus p-HN ATT , p-F Thr plus p-HN ATT or p-F Thr plus p-HN WT , respectively. Our results indicated that the amino acid selection in the F protein was solely responsible for the decreased fusogenic phenotype of the attenuated virus ( Fig. 2a-d) . Although HN ATT was associated with a small increase in the number of syncytia relative to HN WT between 14 and 16 h (Fig. 2a) , this trend did not continue (up to 24 h p.t., data not shown).
To determine whether the fusogenic difference observed between F Thr and F Ala was due to differences in protein expression levels and/or changes in protein processing (e.g. glycosylation), HeLa cells were transfected with p-F Thr or p-F Ala , and at 36 h p.t., the cells were harvested and membrane proteins analysed by Western blotting. Whilst no differences were detected in expression levels of the F protein subunits F 0 and F 1 (P50.667 and P51.000, respectively; Student's t-test) derived from either of the F protein variants (Fig. 3a) , an approximately 3 kDa increase was observed for the F 0 subunit expressed by p-F Thr (78 kDa) relative to that of p-F Ala (75 kDa) (Fig. 3a) . This size increase is consistent with the predicted N-glycosylation at aa 89 (corresponding to nt 265-267) following the selection of a Thr at aa 91 (corresponding to nt 271-273) of the F protein (PROSITE database; Bairoch et al., 1997) . N-Glycosylation at aa 89 was confirmed by peptide : Nglycosidase F treatment of protein extracts isolated from cells transfected with F Thr or F Ala . Deglycosylation yielded F 0 of an equivalent size (58.5 kDa) for the two F variants (data not shown). There was no difference observed in the size of either F 1 variant (63 kDa) (Fig. 3a) . This is consistent with the fact that aa 89 and 91 are present in F 0 and the processed F 2 (Fig. 3b) . As the antibody available to us was specific to the C terminus of F (von Messling et al., 2004) , we could detect the size difference in F 0 , but not F 2 .
IleAVal substitution in the neuroattenuated 88-1961 L protein leads to an increase in transcriptional/replicative activity
To evaluate the role of the amino acid substitution in the polymerase protein, an 88-1961 minigenome assay consisting of a minireplicon (p88-1961CAT) and the viral N, P and L genes was established. Reporter gene (CAT) expression was detected only when all four plasmids (p-N, p-P, p-L and the minireplicon) were co-transfected, confirming the functionality of the system (Fig. 4) . The transcriptional/replication activity of the neuroattenuated polymerase (p-L ATT ) was significantly greater than that of the wild-type polymerase (p-L WT ) across all concentrations of input L plasmid DNA tested (Fig. 4 ) (all P,0.001; Student's t-test).
DISCUSSION
We have reported previously that limited passage in CEF cells of the highly neurovirulent 88-1961 clinical isolate results in virus neuroattenuation, as measured in a neonatal rat assay . The genomes of the clinical isolate (88-1961 WT ) and the attenuated variant (88-1961 ATT ) were sequenced and compared. Amino acid selection/ substitutions were identified only within the F (Ala/Thr91AThr), HN (Ser-466AAsp) and L (Ile-736AVal) proteins. Here, we have shown that each of these single amino acid changes affects protein function and therefore may play a combined role in the neuroattenuation of 88-1961.
The HN glycoprotein is multifunctional, playing key roles in binding of the virus to its cellular receptor (infectious potential), in virus-to-cell and cell-to-cell fusion (spread of virus in the infected tissue) and in neuraminidase activity (release of nascent virions from infected cells). Amino acid substitutions within the HN glycoprotein therefore have the potential to reduce virulence by limiting virus infectivity and spread in the host. Others have reported amino acid changes within the MuV HN protein associated with virus virulence; however, these studies have not examined the effect of such changes on the HN protein in isolation, i.e. changes elsewhere in the virus genome may be responsible for the observed differences in virulence (Afzal et al., 1998; Amexis et al., 2001; Brown et al., 1996; Kovamees et al., 1990; Love et al., 1985) . The Ser-466AAsp substitution in the HN protein identified by our group is of particular significance, being located near the active site affiliated with receptor binding and neuraminidase activity (Crennell et al., 2000) . This substitution is predicted to result in the loss of a glycosylation site (PROSITE database; Bairoch et al., 1997) and possibly leads to structural changes within the protein (Segawa et al., 2000 The effect of the single amino acid selection in the F glycoprotein on protein function was also investigated and demonstrated a dramatic inhibitory effect on fusion activity in transfected cells. The possibility that reduced fusion activity was due to differences in the transfection efficiency of the two F constructs was ruled out by detecting equivalent amounts of F protein expression in the transfected cells. (Merz et al., 1983; Rima et al., 1980) , was also ruled out. All functional domains identified to date in the MuV F protein have been located in the F 1 subunit (Liu et al., 2004; Server et al., 1985; Waxham et al., 1987) . Thus, this is the first report suggesting the location of a critical functional domain within the MuV F 2 subunit. Furthermore, computer analyses predict that this amino acid selection in the F protein of 88-1961 ATT results in glycosylation of the nearby aa 89 (PROSITE database; Bairoch et al., 1997) . Indeed, we observed a 3 kDa increase in size of F Thr relative to F Ala . This difference in size was not observed following deglycosylation of F Thr -and F Alatransfected cell extracts (T. Malik, unpublished observations). Whilst others have reported that loss of glycosylation sites in paramyxovirus F proteins can lead to decreased fusogenicity (Bagai & Lamb 1995 , , Zimmer et al., 2001 , there are few studies indicating that the addition of a glycosylation site can result in decreased fusogenicity (Aguilar et al., 2006) . Additionally, based on homology data from related paramyxoviruses, aa 91 is probably located in a third heptad repeat in which amino acid changes have been suggested by others to affect fusogenicity (Plemper & Compans, 2003) .
Cattaneo
Lastly, our analyses of the Ile-466AVal substitution in the polymerase protein also suggest a role for this mutation in neurovirulence . The MuV polymerase contains six highly conserved domains separated by regions of high variability (Okazaki et al., 1992; Poch et al., 1990) . Domain II contains a highly charged putative RNAbinding motif, whilst domain III is believed to represent an important element of the active site for template recognition and/or phosphodiester bond formation (Okazaki et al., 1992; Poch et al., 1989 Poch et al., , 1990 . Domains II and III together constitute the polymerase module and are essential for viral RNA synthesis (Jablonski et al., 1991 , Muller et al., 1994 Smallwood et al., 2002) . The Ile-466AVal substitution lies within domain III (Poch et al., 1990) . In an attempt to evaluate the impact of the Ile-466AVal substitution on viral transcription/replication, we developed a minigenome system representing the 88-1961 MuV strain. Substitution of the 88-1961 ATT -derived polymerase into the minigenome system resulted in a significant increase in reporter gene activity relative to the 88-1961 WT -derived polymerase. Notably, elevated polymerase activity has also been associated with measles virus attenuation (Bankamp et al., 2002) . Elevated 88-1961 ATT polymerase activity could result in increased viral transcription, triggering a more-effective RIG I-mediated beta interferon (IFN-b) response and hence rapid viral clearance. This hypothesis is based on the recent publication by Plumet et al. (2007) , which proposes that RIG I recognizes mononegavirales transcription and induces a type I interferon (IFN-a/b) response after encountering a free cytosolic 59-triphosphate-ended viral leader transcript. Additional studies are needed to determine whether the increased activity of 88-1961 ATT -derived L is a reflection of increased genome transcription or replication, or both.
In summary, we have identified functional differences in vitro arising from a single amino acid change in each of the 88-1961 HN, F and L proteins, and these changes were associated with neuroattenuation. These studies underline the probable complex and polygenic nature of the common cell-passage method of attenuation of virulent wild-type . Also shown are the locations of the furin cleavage site (RRHKR) that leads to the generation of the F 1 and F 2 subunits, the disulfide bond (S-S) linking F 1 and F 2 , the signal peptide (SP), the fusion peptide (FP), the transmembrane region (TM) and the two heptad repeats (HR1 and HR2). Shaded boxes denote the region recognized by the F-specific anti-cytoplasmic tail polyclonal antibody.
virus strains and the need to determine in this case whether the three amino acid changes act individually or in concert, in vivo, to neuroattenuate 88-1961 WT . Such a determination will require the development of a molecular clone for this viral strain in order to shed much-needed light on the pathogenesis of MuV neurotoxicity and mechanisms of neuroattenuation. These studies may have implications for future vaccine design, not only for MuV, but also for other paramyxoviruses.
